Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Effect of prehydration solution on hearing threshold after chemotherapy in patients with head and neck cancers: a retrospective study

  • Dongbin Ahn (Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University) ;
  • Kyu-Yup Lee (Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University) ;
  • Eunjung Oh (Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University) ;
  • Minji Oh (Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University) ;
  • Boseung Jung (Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University) ;
  • Da Jung Jung (Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University)
  • 투고 : 2022.04.20
  • 심사 : 2022.07.19
  • 발행 : 2023.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The study aimed to evaluate the effect of prehydration solution on hearing thresholds after cisplatin chemotherapy. Methods: In this retrospective cohort study, we reviewed the data of patients who underwent ≥3 courses of cisplatin-based chemotherapy for locally advanced head and neck cancers at a tertiary referral center (n=64). The dextrose solution (DW) group (n=26) received 2 L of normal saline and 1 L of 5% dextrose. The Hartmann solution (HS) group (n=38) received 2 L of normal saline and 1 L of HS. Hearing data were measured 1 day before starting the first course of chemotherapy, and again 20 days after the first, second, and third courses of chemotherapy. The severity of hearing loss was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE). Results: Thresholds at all frequencies after chemotherapy were greater in the DW group than in the HS group. The increase in thresholds in 1 to 4 kHz after the third course of chemotherapy was greater in the DW group than in the HS group. CTCAE grades after the second and third courses of chemotherapy were greater in the DW group than in the HS group. Logistic regression showed that the odds ratio for CTCAE grade 3 or 4 after the third course of chemotherapy in the DW group was 4.84 on univariate analysis. Conclusion: Prehydration using a solution with salt was associated with a decrease in change in hearing thresholds after cisplatin chemotherapy in patients with head and neck cancers.

키워드

과제정보

This work was supported by Biomedical Research Institute grant, Kyungpook National University Hospital (2020).

참고문헌

  1. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698-9. https://doi.org/10.1038/205698a0
  2. Laurell G, Bagger-Sjoback D. Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 1991;20:158-67.
  3. Wu X, Li X, Song Y, Li H, Bai X, Liu W, et al. Allicin protects auditory hair cells and spiral ganglion neurons from cisplatin - induced apoptosis. Neuropharmacology 2017;116:429-40. https://doi.org/10.1016/j.neuropharm.2017.01.001
  4. Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun 2017;8:1654.
  5. Santos NA, Ferreira RS, Santos AC. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol 2020;136:111079.
  6. Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol 2018;22:210-44. https://doi.org/10.1007/s10157-017-1448-z
  7. Earhart RH, Martin PA, Tutsch KD, Erturk E, Wheeler RH, Bull FE. Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. Cancer Res 1983;43:1187-94.
  8. Daley-Yates PT, McBrien DC. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem Pharmacol 1985;34:2363-9. https://doi.org/10.1016/0006-2952(85)90795-6
  9. Ahn D, Lee GJ, Sohn JH, Lee JE. Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma. Cancer Med 2020;9:9256-65. https://doi.org/10.1002/cam4.3529
  10. Common Terminology Criteria for Adverse Events (CTCAE v5.0). U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2017 [cited 2022 Jun 5]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50.
  11. Trendowski MR, El Charif O, Dinh PC Jr, Travis LB, Dolan ME. Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res 2019;25:1147-55. https://doi.org/10.1158/1078-0432.CCR-18-2244
  12. More SS, Akil O, Ianculescu AG, Geier EG, Lustig LR, Giacomini KM. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 2010;30:9500-9. https://doi.org/10.1523/JNEUROSCI.1544-10.2010
  13. Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res 2014;34:547-50.
  14. Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett 2015;237:219-27. https://doi.org/10.1016/j.toxlet.2015.06.012
  15. Duval M, Daniel SJ. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. J Otolaryngol Head Neck Surg 2012;41:309-15.
  16. Freyer DR, Brock PR, Chang KW, Dupuis LL, Epelman S, Knight K, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health 2020;4:141-50. https://doi.org/10.1016/S2352-4642(19)30336-0
  17. Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol 2016;2016:1809394.
  18. Paken J, Govender CD, Pillay M, Sewram V. A review of cisplatin-associated ototoxicity. Semin Hear 2019;40:108-21. https://doi.org/10.1055/s-0039-1684041
  19. Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003;52:13-8. https://doi.org/10.1007/s00280-003-0620-1
  20. Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, et al. Cisplatin-induced ototoxicity: updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm 2021;163:60-71. https://doi.org/10.1016/j.ejpb.2021.03.008
  21. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23. https://doi.org/10.1016/j.ctrv.2006.09.006